Copenhagen, March 12th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today an agreement with Hyphens Pharma Pte. Ltd., a subsidiary of Hyphens Pharma International Limited (“Hyphens”), under which Hyphens has been granted exclusive ASEAN (Association of Southeast Asian) region rights to register and commercialize MC2’s Wynzora® Cream for the treatment of plaque psoriasis.
In exchange, MC2 Therapeutics will receive upfront and marketing approval milestones of EUR 2.5 million in addition to sales milestone payments and double-digit royalties on the ASEAN net sales of Wynzora® Cream.
“Hyphens is a leading specialty pharma company focused on the commercialization of innovative pharmaceutical products in the ASEAN region. It has a clear ambition and strategy to grow its dermatology franchise and is an excellent partner for MC2 to leverage Wynzora® in the region, a large and growing market with over 600 million people,” said Jesper J. Lange, Chief Executive Officer of MC2 Therapeutics. “This deal substantiates our strategy to make Wynzora® available to as many patients suffering from plaque psoriasis as possible globally, as we continue to develop and expand our pipeline of innovative first-in-class drug candidates within immunology and inflammation.”
See Wah Lim, Chairman and CEO of Hyphens Pharma said: “MC2’s commitment to develop novel treatment paradigms for skin diseases is synergistic with Hyphens’ presence and ambition to be a regional leader in ASEAN. Wynzora® is a proven effective treatment for plaque psoriasis in the US and EU. Leveraging our strong regulatory and commercial capabilities, we will work closely with MC2 to accelerate the launch of Wynzora® in the ASEAN region, which will benefit Asian patients suffering from psoriasis.”
Hyphens will be responsible for the regulatory approval and commercialization of Wynzora® Cream in the ASEAN region with the oversight of a joint steering committee comprised of individuals from both companies. The transaction is effective immediately upon the execution of the License Agreement.
About Wynzora® Cream
Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021.
About MC2 Therapeutics A/S
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking.
Its pipeline includes two first-in-class drug candidates both in Phase 2 clinical development, with novel modes of action and potential in multiple indications (“I&I pipeline in a product”).
For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com
Contacts:
Lonni Goltermann, +45 2018 1111, investor@mc2therapeutics.com
About Hyphens Pharma International Limited
Hyphens Pharma International Limited and its subsidiaries (the “Group”) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines, and is supplemented by a marketing and distribution network covering 14 other markets. The Group’s core business comprises Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets, and sells its own proprietary range of dermatological and health supplement products.
For additional information, please visit https://www.hyphensgroup.com
BACK
